Gilead Sciences Boston Consulting Group Matrix
Actionable Strategy Starts Here
Gilead’s product portfolio sits at a crossroads of high-growth antivirals and mature therapeutic franchises—our BCG Matrix preview flags likely Stars in newer antivirals, Cash Cows in established HIV treatments, and potential Question Marks in emerging oncology efforts. This snapshot highlights where cash generation and reinvestment tensions may shape strategic choices. Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
Trodelvy in Oncology
Trodelvy (sacituzumab govitecan) is Gilead’s high-growth star: FY2025 revenue hit $3.1B (company report, 2025), led by 42% share in U.S. triple-negative breast cancer and rapid uptake in bladder cancer.
Gilead is expanding indications into non-small cell lung cancer and other solid tumors; ongoing Phase 3 programs (≈10,000 patients across trials) keep Trodelvy in growth mode.
Despite strong sales, Trodelvy requires heavy spend—R&D and SG&A rose to $1.2B in 2025—to outpace emerging ADC competitors and secure global market share.
Biktarvy for HIV Treatment
Biktarvy (Gilead Sciences) retains star status: >50% US single-tablet INSTI market share and ~$7.5B global sales in 2024, but the market shifts to long-acting injectables so growth remains high-risk.
Gilead must invest in defense—estimated $500M+ annual spend on patient-switch programs, adherence support, and promotional campaigns—to preserve channel dominance against competitors like Cabenuva.
The drug generates massive cashflow (operating margin ~45% on Biktarvy sales) yet needs high reinvestment for ecosystem protection and line extensions such as pediatric and combo formulations.
Yescarta in Cell Therapy
Yescarta (axicabtagene ciloleucel) is a market leader in CAR-T for large B-cell lymphoma, with 2024 global sales around $1.7 billion and >40% share in second-line CAR-T launches.
Oncology cell therapy demand is rising ~18% CAGR through 2028 as manufacturing costs fall ~25% per batch and more payers cover second-line use.
Gilead invested >$1.5 billion since 2020 in certified treatment centers and expanded manufacturing, defending share versus Bristol Myers Squibb and Novartis.
Anito-cel for Multiple Myeloma
Anito-cel for multiple myeloma is a Star in Gilead’s BCG matrix entering 2026 after expected launch and fast uptake; analysts model peak sales of $3.2–4.5B by 2030 given 15–20% annual growth in BCMA-targeted therapy demand.
It targets high-growth oncology with unmet need for effective BCMA therapies; Gilead plans >$1.2B in launch-year commercial and manufacturing investment to seize share and make it a hematology pillar.
- Star status: launched 2026, rapid uptake
- Market: BCMA segment growing ~15–20% CAGR
- Financials: peak sales $3.2–4.5B by 2030
- Investment: >$1.2B launch-year spend
Lenacapavir for HIV Prevention
Following 2024 PrEP trial wins, Lenacapavir is a Star for Gilead Sciences, tapping a preventive HIV market growing ~8% CAGR to 2030; twice-yearly dosing boosts adherence vs daily pills and supports premium pricing (~$15–20k/year estimated for injectables in 2025 market comps).
Its long-acting profile demands heavy commercial buildout—cold-chain, clinic injection capacity—and Gilead projects Lenacapavir to drive mid-single-digit percentage revenue growth by 2027 as it shifts HIV care to injectables.
- Twice-yearly dosing: major adherence edge
- 2025 price comps: ~$15–20k/year
- HIV prevention market: ~8% CAGR to 2030
- Requires clinic infrastructure, cold-chain logistics
Top Biotech Revenue Stars: Trodelvy, Biktarvy, Yescarta, Anito‑cel, Lenacapavir
Stars: Trodelvy $3.1B (FY2025), Biktarvy ~$7.5B (2024), Yescarta $1.7B (2024), Anito-cel peak $3.2–4.5B (2030 est.), Lenacapavir priced ~$15–20k/yr (2025 comps).
| Asset | 2024–25 sales/price | Growth/notes |
|---|---|---|
| Trodelvy | $3.1B | Expanding indications, heavy R&D |
| Biktarvy | $7.5B | Defensive spend vs LA injectables |
| Yescarta | $1.7B | CAR-T leader, scale investments |
| Anito-cel | Peak $3.2–4.5B | Launch 2026 est., BCMA demand |
| Lenacapavir | $15–20k/yr | PrEP LA, requires clinic ops |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix of Gilead’s portfolio: identifies Stars (growth drivers), Cash Cows, Question Marks to invest, and Dogs to divest.
Customizable Excel Spreadsheet
One-page Gilead BCG Matrix placing each therapeutic area in a quadrant for rapid strategic review.
Cash Cows
Descovy for HIV
Descovy for HIV remains a cash cow for Gilead, holding ~30–35% U.S. market share in treatment and ~25% in PrEP as of 2025, generating roughly $2.1B revenue in 2024 and strong free cash flow margins.
HIV is a mature market, and Gilead’s decade-long provider relationships keep marketing spend low—R&D/SG&A allocated per-dollar revenue is materially below new oncology launches.
That steady cash flow funds Gilead’s push into oncology and inflammation, where planned 2025 M&A and internal investments target ~$3–4B incremental spend over 2025–2027.
Veklury for COVID-19
By end-2025 Veklury (remdesivir) is a standard hospital treatment for viral pneumonia, delivering stable sales of about $2.1bn annually and holding ~35% hospital-market share in major markets.
Post-pandemic growth slowed, but high gross margins (~62%) from scaled manufacturing keep it a cash cow, funding ~30% of Gilead’s 2025 dividend payments and aiding debt service on $18bn net debt.
Epclusa for Hepatitis C
Epclusa (sofosbuvir/velpatasvir) remains a dominant Hepatitis C therapy; as of 2024 Gilead reported HCV net product sales around $1.6B and market share above 50% in treated genotypes, while global treated prevalence fell ~40% since 2015 to ~58M viremic cases in 2023, stabilizing the patient pool.
With few new entrants and limited incremental innovation, Epclusa requires minimal promotional spend—Gilead’s SG&A intensity for antivirals stayed near 18% in 2024—helping sustain share without high marketing outlays.
Gross margins on Epclusa-like DAAs exceed 70%, generating cash that funded Gilead’s 2024 R&D budget of $6.1B, supporting riskier oncology and immunology programs where returns are more volatile.
Genvoya for HIV Management
Genvoya, a multi-tablet HIV regimen approved 2015, remains a cash cow for Gilead Sciences with roughly $1.2B in 2024 net product sales, serving a stable legacy patient base that seldom switches; minimal marketing spend and low churn keep margins high.
- ~$1.2B 2024 sales
- High gross margin, low marketing
- Stable market share in legacy patients
- Low churn unless medically needed
Viread for Chronic HBV
Viread for chronic HBV remains a cash cow for Gilead Sciences, delivering steady revenues—approximately $1.2 billion in FY 2024—from a mature global HBV market with low single-digit annual growth.
Gilead optimizes manufacturing and supply-chain efficiency over market expansion to sustain margins, redirecting harvested cash toward high-growth CAR-T programs and oncology R&D.
- FY24 revenue ≈ $1.2B
- HBV market growth: low single-digit %
- Focus: cost, supply-chain efficiency
- Proceeds fund CAR-T and oncology R&D
Gilead’s five cash cows: $7.2B revenue, ~70% margins fueling R&D and debt service
Descovy, Veklury, Epclusa, Genvoya, and Viread are Gilead cash cows, collectively generating ~$7.2B in 2024 revenue, high gross margins (62–75%), low SG&A intensity (~18%), and funding $6.1B R&D plus dividend/debt service on $18B net debt.
| Product | 2024 rev ($B) | Margin | Role |
|---|---|---|---|
| Descovy | 2.1 | ~70% | HIV cash cow |
| Veklury | 2.1 | 62% | Hospital staple |
| Epclusa | 1.6 | >70% | HCV leader |
| Genvoya | 1.2 | ~70% | Legacy HIV |
| Viread | 1.2 | ~70% | HBV steady |
Delivered as Shown
Gilead Sciences BCG Matrix
The file you're previewing on this page is the final Gilead Sciences BCG Matrix you'll receive after purchase; no watermarks or demo content—just a fully formatted, analysis-ready report designed for strategic clarity and professional use. This preview mirrors the exact document sent to your inbox—market-backed insights, precise positioning of product lines and therapeutic areas, and actionable recommendations. Upon purchase you’ll get the editable, printable file immediately for presentations, planning, or client deliverables.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Actionable Strategy Starts Here
Gilead’s product portfolio sits at a crossroads of high-growth antivirals and mature therapeutic franchises—our BCG Matrix preview flags likely Stars in newer antivirals, Cash Cows in established HIV treatments, and potential Question Marks in emerging oncology efforts. This snapshot highlights where cash generation and reinvestment tensions may shape strategic choices. Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
Trodelvy in Oncology
Trodelvy (sacituzumab govitecan) is Gilead’s high-growth star: FY2025 revenue hit $3.1B (company report, 2025), led by 42% share in U.S. triple-negative breast cancer and rapid uptake in bladder cancer.
Gilead is expanding indications into non-small cell lung cancer and other solid tumors; ongoing Phase 3 programs (≈10,000 patients across trials) keep Trodelvy in growth mode.
Despite strong sales, Trodelvy requires heavy spend—R&D and SG&A rose to $1.2B in 2025—to outpace emerging ADC competitors and secure global market share.
Biktarvy for HIV Treatment
Biktarvy (Gilead Sciences) retains star status: >50% US single-tablet INSTI market share and ~$7.5B global sales in 2024, but the market shifts to long-acting injectables so growth remains high-risk.
Gilead must invest in defense—estimated $500M+ annual spend on patient-switch programs, adherence support, and promotional campaigns—to preserve channel dominance against competitors like Cabenuva.
The drug generates massive cashflow (operating margin ~45% on Biktarvy sales) yet needs high reinvestment for ecosystem protection and line extensions such as pediatric and combo formulations.
Yescarta in Cell Therapy
Yescarta (axicabtagene ciloleucel) is a market leader in CAR-T for large B-cell lymphoma, with 2024 global sales around $1.7 billion and >40% share in second-line CAR-T launches.
Oncology cell therapy demand is rising ~18% CAGR through 2028 as manufacturing costs fall ~25% per batch and more payers cover second-line use.
Gilead invested >$1.5 billion since 2020 in certified treatment centers and expanded manufacturing, defending share versus Bristol Myers Squibb and Novartis.
Anito-cel for Multiple Myeloma
Anito-cel for multiple myeloma is a Star in Gilead’s BCG matrix entering 2026 after expected launch and fast uptake; analysts model peak sales of $3.2–4.5B by 2030 given 15–20% annual growth in BCMA-targeted therapy demand.
It targets high-growth oncology with unmet need for effective BCMA therapies; Gilead plans >$1.2B in launch-year commercial and manufacturing investment to seize share and make it a hematology pillar.
- Star status: launched 2026, rapid uptake
- Market: BCMA segment growing ~15–20% CAGR
- Financials: peak sales $3.2–4.5B by 2030
- Investment: >$1.2B launch-year spend
Lenacapavir for HIV Prevention
Following 2024 PrEP trial wins, Lenacapavir is a Star for Gilead Sciences, tapping a preventive HIV market growing ~8% CAGR to 2030; twice-yearly dosing boosts adherence vs daily pills and supports premium pricing (~$15–20k/year estimated for injectables in 2025 market comps).
Its long-acting profile demands heavy commercial buildout—cold-chain, clinic injection capacity—and Gilead projects Lenacapavir to drive mid-single-digit percentage revenue growth by 2027 as it shifts HIV care to injectables.
- Twice-yearly dosing: major adherence edge
- 2025 price comps: ~$15–20k/year
- HIV prevention market: ~8% CAGR to 2030
- Requires clinic infrastructure, cold-chain logistics
Top Biotech Revenue Stars: Trodelvy, Biktarvy, Yescarta, Anito‑cel, Lenacapavir
Stars: Trodelvy $3.1B (FY2025), Biktarvy ~$7.5B (2024), Yescarta $1.7B (2024), Anito-cel peak $3.2–4.5B (2030 est.), Lenacapavir priced ~$15–20k/yr (2025 comps).
| Asset | 2024–25 sales/price | Growth/notes |
|---|---|---|
| Trodelvy | $3.1B | Expanding indications, heavy R&D |
| Biktarvy | $7.5B | Defensive spend vs LA injectables |
| Yescarta | $1.7B | CAR-T leader, scale investments |
| Anito-cel | Peak $3.2–4.5B | Launch 2026 est., BCMA demand |
| Lenacapavir | $15–20k/yr | PrEP LA, requires clinic ops |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix of Gilead’s portfolio: identifies Stars (growth drivers), Cash Cows, Question Marks to invest, and Dogs to divest.
Customizable Excel Spreadsheet
One-page Gilead BCG Matrix placing each therapeutic area in a quadrant for rapid strategic review.
Cash Cows
Descovy for HIV
Descovy for HIV remains a cash cow for Gilead, holding ~30–35% U.S. market share in treatment and ~25% in PrEP as of 2025, generating roughly $2.1B revenue in 2024 and strong free cash flow margins.
HIV is a mature market, and Gilead’s decade-long provider relationships keep marketing spend low—R&D/SG&A allocated per-dollar revenue is materially below new oncology launches.
That steady cash flow funds Gilead’s push into oncology and inflammation, where planned 2025 M&A and internal investments target ~$3–4B incremental spend over 2025–2027.
Veklury for COVID-19
By end-2025 Veklury (remdesivir) is a standard hospital treatment for viral pneumonia, delivering stable sales of about $2.1bn annually and holding ~35% hospital-market share in major markets.
Post-pandemic growth slowed, but high gross margins (~62%) from scaled manufacturing keep it a cash cow, funding ~30% of Gilead’s 2025 dividend payments and aiding debt service on $18bn net debt.
Epclusa for Hepatitis C
Epclusa (sofosbuvir/velpatasvir) remains a dominant Hepatitis C therapy; as of 2024 Gilead reported HCV net product sales around $1.6B and market share above 50% in treated genotypes, while global treated prevalence fell ~40% since 2015 to ~58M viremic cases in 2023, stabilizing the patient pool.
With few new entrants and limited incremental innovation, Epclusa requires minimal promotional spend—Gilead’s SG&A intensity for antivirals stayed near 18% in 2024—helping sustain share without high marketing outlays.
Gross margins on Epclusa-like DAAs exceed 70%, generating cash that funded Gilead’s 2024 R&D budget of $6.1B, supporting riskier oncology and immunology programs where returns are more volatile.
Genvoya for HIV Management
Genvoya, a multi-tablet HIV regimen approved 2015, remains a cash cow for Gilead Sciences with roughly $1.2B in 2024 net product sales, serving a stable legacy patient base that seldom switches; minimal marketing spend and low churn keep margins high.
- ~$1.2B 2024 sales
- High gross margin, low marketing
- Stable market share in legacy patients
- Low churn unless medically needed
Viread for Chronic HBV
Viread for chronic HBV remains a cash cow for Gilead Sciences, delivering steady revenues—approximately $1.2 billion in FY 2024—from a mature global HBV market with low single-digit annual growth.
Gilead optimizes manufacturing and supply-chain efficiency over market expansion to sustain margins, redirecting harvested cash toward high-growth CAR-T programs and oncology R&D.
- FY24 revenue ≈ $1.2B
- HBV market growth: low single-digit %
- Focus: cost, supply-chain efficiency
- Proceeds fund CAR-T and oncology R&D
Gilead’s five cash cows: $7.2B revenue, ~70% margins fueling R&D and debt service
Descovy, Veklury, Epclusa, Genvoya, and Viread are Gilead cash cows, collectively generating ~$7.2B in 2024 revenue, high gross margins (62–75%), low SG&A intensity (~18%), and funding $6.1B R&D plus dividend/debt service on $18B net debt.
| Product | 2024 rev ($B) | Margin | Role |
|---|---|---|---|
| Descovy | 2.1 | ~70% | HIV cash cow |
| Veklury | 2.1 | 62% | Hospital staple |
| Epclusa | 1.6 | >70% | HCV leader |
| Genvoya | 1.2 | ~70% | Legacy HIV |
| Viread | 1.2 | ~70% | HBV steady |
Delivered as Shown
Gilead Sciences BCG Matrix
The file you're previewing on this page is the final Gilead Sciences BCG Matrix you'll receive after purchase; no watermarks or demo content—just a fully formatted, analysis-ready report designed for strategic clarity and professional use. This preview mirrors the exact document sent to your inbox—market-backed insights, precise positioning of product lines and therapeutic areas, and actionable recommendations. Upon purchase you’ll get the editable, printable file immediately for presentations, planning, or client deliverables.
